Back
Kiniksa Pharmaceuticals Quote, Financials, Valuation and Earnings
9,530x the last time this happened
Here's what our expert says you should buy before April 14.
Buy
58
KNSA
Kiniksa Pharmaceuticals
Last Price:
17.88
Seasonality Move:
4.08%
7 Day Trial
ALL ACCESS PASS
$
7
MarketBeat Alert: Escape the market madness with 7 stocks to buy and hold
The result is a select group of high-quality blue-chip stocks.Kiniksa Pharmaceuticals Price Quote
$17.88
Kiniksa Pharmaceuticals Key Stats
Buy
58
Kiniksa Pharmaceuticals (KNSA)
is a Buy
Day range:
$17.45 - $18.05
52-week range:
$10.65 - $22.09
Dividend yield:
0%
P/E ratio:
89.40
P/S ratio:
4.30
P/B ratio:
2.94%
Volume:
331.6K
Avg. volume:
380.2K
1-year change:
60.36%
Market cap:
$1.3B
Revenue:
$270.3M
EPS:
$0.11
How Much Does Kiniksa Pharmaceuticals Make?
-
How Much Are Kiniksa Pharmaceuticals's Sales Annually?
KNSA Revenues are $270.3M -
How Much Profit Does Kiniksa Pharmaceuticals's Make A Year?
KNSA net income is $14.1M
Is Kiniksa Pharmaceuticals Growing As A Company?
-
What Is Kiniksa Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.65% -
What Is Kiniksa Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Kiniksa Pharmaceuticals Stock Price Performance
-
Did Kiniksa Pharmaceuticals Stock Go Up Last Month?
Kiniksa Pharmaceuticals share price went down by -10.47% last month -
Did KNSA's Share Price Rise Over The Last Year?
KNSA share price rose by 60.36% over the past 1 year
What Is Kiniksa Pharmaceuticals 52-Week High & Low?
-
What Is Kiniksa Pharmaceuticals’s 52-Week High Share Price?
Kiniksa Pharmaceuticals has traded as high as $22.09 over the past 52 weeks -
What Is Kiniksa Pharmaceuticals’s 52-Week Low Share Price?
Kiniksa Pharmaceuticals has traded as low as $10.65 over the past 52 weeks
Kiniksa Pharmaceuticals Price To Free Cash Flow
-
Is Kiniksa Pharmaceuticals Stock Overvalued?
Kiniksa Pharmaceuticals is trading at a price to free cash flow ratio of 60.73 -
Is Kiniksa Pharmaceuticals Stock Undervalued?
Kiniksa Pharmaceuticals EV to Free Cash Flow ratio is 49.37 -
What Is Kiniksa Pharmaceuticals’s Price Earnings Growth Ratio?
KNSA PEG ratio is 0.00 -
Is Kiniksa Pharmaceuticals Trading At A Premium To Earnings?
Kiniksa Pharmaceuticals EV to EBIT ratio is 0.00
Is It Risky To Buy Kiniksa Pharmaceuticals?
-
How Much Debt Does Kiniksa Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Kiniksa Pharmaceuticals Have?
Cash and short term investments quarterly total is $213.6M -
What Is Kiniksa Pharmaceuticals’s Book Value Per Share?
Book value per share is 6.10
Is Kiniksa Pharmaceuticals Cash Flow Positive?
-
What Is KNSA Cash Flow From Operations?
Cash flow from operations (TTM) is $21.6M -
What Is Kiniksa Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is $5M -
What Is Kiniksa Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is $33.9M
Kiniksa Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
KNSA return on invested capital is 2.08% -
What Is Kiniksa Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 1.76% -
What Is KNSA Return On Equity?
ROE is a measure of profitability and is 2.08%
Kiniksa Pharmaceuticals Earnings Date & Stock Price
-
What Is Kiniksa Pharmaceuticals's Stock Price Today?
A single share of KNSA can be purchased today for 17.88 -
What Is Kiniksa Pharmaceuticals’s Stock Symbol?
Kiniksa Pharmaceuticals trades on the nasdaq under the ticker symbol: KNSA -
When Is Kiniksa Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Kiniksa Pharmaceuticals is scheduled on July 25, 2024 -
When Is KNSA's next ex-dividend date?
Kiniksa Pharmaceuticals's next ex-dividend date is June 17, 2020 -
How To Buy Kiniksa Pharmaceuticals Stock?
You can buy Kiniksa Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Kiniksa Pharmaceuticals Competitors
-
Who Are Kiniksa Pharmaceuticals's Competitors?
Below is a list of companies who compete with Kiniksa Pharmaceuticals or are related in some way:
Kiniksa Pharmaceuticals Dividend Yield
Data Unavailable
Kiniksa Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | -212.5% |
| Revenue: | 65.18% | 1.78% |
Analyst Recommendations
| Buy Recommendations: | 3 |
|---|---|
| Hold Recommendations: | 0 |
| Sell Recommendations: | 0 |
| Price Target: | 29.20 |
| Upside from Last Price: | 63.31% |